This secondary analysis of data from the FIDELIO-DKD trial was presented May 17 at ACC.21 and published in the Journal of the American College of Cardiology. 

The FDA has received complaints about 135 injuries so far. 

The study's authors believe they are the first group to investigate the real-time relationship between alcohol consumption and AFib events.

Certain patients face a "significantly greater risk of AFib" if they take fish oil supplements, the study's authors reported. 

The authors evaluated data from more than 2.1 million patients, sharing their findings in Circulation.

Researchers called for better guidelines that cover when clinicians should consider stopping anticoagulation therapy for patients with AFib. The risks of such medication, they observed, may often outweigh the benefits. 

The TAP-CHF trial is expected to enroll up to 100 AFib patients with a history of HFpEF. 

“What surprised me is that such small changes in electrolyte values have such dramatic effects,” one researcher said. 

Catheter ablation is associated with better outcomes for AFib patients, researchers noted, but beginning treatment with just antiarrhythmic medications may be the most practical option. 

Marijuana users with a cardiac arrhythmia may face a heightened risk of in-hospital mortality, new research suggests. 

The organization is accepting public comments on this topic until May 17.